Total submissions: 6
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
CFTR2 | RCV000576558 | SCV000677628 | pathogenic | Cystic fibrosis | 2017-03-17 | reviewed by expert panel | research | |
CFTR- |
RCV000576558 | SCV001169517 | pathogenic | Cystic fibrosis | 2018-01-29 | criteria provided, single submitter | curation | |
Women's Health and Genetics/Laboratory Corporation of America, |
RCV000576558 | SCV001372282 | pathogenic | Cystic fibrosis | 2020-06-01 | criteria provided, single submitter | clinical testing | Variant summary: CFTR c.2645G>A (p.Trp882X) results in a premature termination codon, predicted to cause a truncation of the encoded protein or absence of the protein due to nonsense mediated decay, which are commonly known mechanisms for disease. Truncations downstream of this position have been classified as pathogenic by our laboratory. The variant was absent in 251468 control chromosomes. c.2645G>A has been reported in the literature in individuals affected with Cystic Fibrosis (example, Clausters_2000, LeMarchal_2001, Sermet-Gaudelus_2010, Lucarelli_2017, Dewulf_2015). These data indicate that the variant is likely to be associated with disease. To our knowledge, no experimental evidence demonstrating an impact on protein function has been reported. Two submitters including an expert panel (CFTR2) have submitted clinical-significance assessments for this variant to ClinVar after 2014 without evidence for independent evaluation. All submitters classified the variant as pathogenic. Based on the evidence outlined above, the variant was classified as pathogenic. |
Baylor Genetics | RCV003466905 | SCV004215772 | pathogenic | Bronchiectasis with or without elevated sweat chloride 1 | 2022-08-13 | criteria provided, single submitter | clinical testing | |
Clin |
RCV000576558 | SCV000679355 | not provided | Cystic fibrosis | no assertion provided | literature only | ||
Natera, |
RCV001826644 | SCV002080784 | pathogenic | CFTR-related disorder | 2017-03-17 | no assertion criteria provided | clinical testing |